Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when STOK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Auditor Change (new) — The company dismissed KPMG and replaced them with Ernst & Young, though the filing indicates no disagreements or reportable events occurred.
Stoke Therapeutics replaces auditor KPMG with Ernst & Young effective March 23, 2026
Filed March 27, 2026 · Period ending March 23, 2026 · ~1 min read
Key Changes
-
high
The Audit Committee dismissed KPMG as independent auditor and appointed Ernst & Young for fiscal year 2026, effective March 23. The company states there were no disagreements with KPMG on accounting principles or auditing procedures.
Item 4.01 verify on EDGAR → -
medium
KPMG's audit reports for 2024 and 2025 were clean with no adverse opinions, disclaimers, or qualifications, suggesting the auditor change was not driven by financial reporting disputes or issues.
Item 4.01 verify on EDGAR → -
medium
The company had not previously consulted with Ernst & Young on any accounting or auditing matters during the two most recent fiscal years prior to their appointment.
Item 4.01 verify on EDGAR → -
medium
KPMG provided a letter dated March 27, 2026, filed as an exhibit, which typically addresses whether there were any disagreements or reportable events during their engagement.
Exhibit 16.1 verify on EDGAR →
Summary
Stoke Therapeutics dismissed KPMG as its independent auditor and appointed Ernst & Young effective March 23, 2026. While auditor changes can signal underlying issues, the company explicitly states there were no disagreements with KPMG on accounting principles, financial disclosures, or auditing procedures. KPMG's audit reports for the past two fiscal years were clean, with no adverse opinions or qualifications, which suggests this was a business decision rather than a response to financial reporting problems.
For retail investors, auditor changes warrant attention because they can sometimes indicate accounting disputes or financial irregularities. However, the clean audit history and absence of reported disagreements reduce immediate concern. The key item to monitor is Ernst & Young's first audit report for fiscal year 2026, which will provide insight into whether the transition was truly routine or if any issues emerge under the new auditor's review.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Stoke Therapeutics filed a letter from KPMG LLP dated March 27, 2026, typically indicating an auditor change or resignation.
Added in current filing · verify on EDGAR →
Letter from KPMG LLP, dated March 27, 2026
The company filed a letter from KPMG LLP dated March 27, 2026 as Exhibit 16.1. Such letters are typically filed when there is a change in the company's independent registered public accounting firm, and the letter addresses whether there were any disagreements or reportable events during the auditor's engagement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify